### Editorial commentary

1299 Optinurin inclusions in proximal hereditary motor and sensory neuropathy (HMSN-P): familial amyotrophic lateral sclerosis with sensory neuropathy?  
M Nakagawa

### Neuropsychiatry

**1300** Diagnosis and treatment of psychogenic parkinsonism  
J Jankovic

1304 Grey matter abnormality in autism spectrum disorder: an activation likelihood estimation meta-analysis study  
F Cauda, E Geda, K Sacco, F D’Agata, S Duca, G Geminiani, R Keller

1314 Xenomelia: a new right parietal lobe syndrome  
P D McGeech, D Brang, T Song, R R Lee, M Huang, V S Ramachandran

1320 Dissecting the Gilles de la Tourette spectrum: a factor analytic study on 639 patients  
A E Cavanna, H D Critchley, M Orth, J S Stern, M-B Young, M M Robertson

1324 Delayed experience of volition in Gilles de la Tourette syndrome  
G Moreto, P Schwingenschuh, P Katschnig, K P Bhatia, P Haggard

### Epilepsy

1328 Seizure recurrence after antiepileptic drug withdrawal and the implications for driving: further results from the MRC Antiepileptic Drug Withdrawal Study and a systematic review  
L J Bonnett, A Shuballa, C Tudor-Smith, P R Williamson, A G Marson

1334 Detecting deficits of sustained visual attention in delirium  

1339 Structural neuroanatomy of face processing in frontotemporal lobar degeneration  
R Oman, J D Rohrer, J C Hillstone, J D Warrren

### Multiple sclerosis

1341 Mitoxantrone prior to interferon-beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial  
G Edan, G Comi, E Le Page, E Leray, M A Rocca, M Filippi, for The French–Italian Mitoxantrone Interferon-beta-1b Trial Group

1351 Familial recurrence risks for multiple sclerosis in Australia  
C O’Geran, S Freeman, B V Taylor, H Buzzkueven, Australian and New Zealand MS Genetics Consortium (ANZgene), S A Broadley

1355 Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica  

1360 Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes  
A Nagashita, M Takaqi, A Umemura, M Tanaka, Y Kitagawa, M Matsui, M Nishizawa, K Sakimura, K Tanaka

### Cerebrovascular disease

1365 Factors associated with quality of life in 7-year survivors of stroke  
M J Leach, S L Gall, H M Dewey, R A L Macdonell, A G Thrift

1372 Mutations in TGFBR2 gene cause spontaneous cervical artery dissection  
A Pezzini, B Decca, E De Zotto, M Ritelli, M Carletti, G Tonelleri, P Bovi, A Giassi, I Volonghi, P Costa, M Magon, A Pavodani, S Barlati, M Colombi
Neurosurgery
1375 Hippocampal resection length and memory outcome in selective epilepsy surgery
C Helmstaedter, S Roeske, S Kaaden, C E Elger, J Schramm

Movement disorders
1382 Urinary dysfunction in early and untreated Parkinson’s disease
T Uchiyama, R Sakakibara, T Yamamoto, T Ito, C Yamaguchi, Y Awa, M Yanagisawa, Y Higuchi, Y Sato, T Ichikawa, T Yamanishi, T Hattori, S Kuwabara

1387 Maximal subthalamic beta hypersynchrony of the local field potential in Parkinson’s disease is located in the central region of the nucleus
C de Solages, B C Hill, H Yu, J M Henderson, H Bronte-Stewart

1390 Once-weekly risedronate for prevention of hip fracture in women with Parkinson’s disease: a randomised controlled trial
Y Sato, J Iwamoto, Y Honda

Neuromuscular disease
1394 Muscle ischaemia in patients with orthostatic hypotension assessed by velocity recovery cycles
A M Humm, H Bostock, R Troller, W J Z’Graggen

Neuro-inflammatory disease
1399 Antiglycine-receptor encephalomyelitis with rigidity
N Mas, A Saiz, M I Leite, P Waters, M Baron, D Castaño, I Sabater, A Vincent, F Graus

PostScript
1402 Letters